Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonyl Reductase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111172124B details a YOL151W mutant for high-concentration synthesis, offering cost-effective pharma intermediate manufacturing.
Patent CN111686809A reveals a robust dual-enzyme system for producing chiral statin intermediates, offering enhanced stability and cost-effective manufacturing solutions.
Patent CN110387359A enables high-purity statin intermediate production via engineered carbonyl reductase mutants ensuring supply chain stability.
Patent CN103695443A reveals ChKRED03 for synthesizing chiral alcohols. Offers cost reduction in chiral alcohol manufacturing and reliable supply chain solutions.
Novel carbonyl reductase mutant enables high-purity chiral intermediate synthesis with reduced solvent waste and cost for pharmaceutical supply chains.
Patent CN103937759B reveals a novel biocatalytic route for statin intermediates. Discover cost reduction and supply chain reliability advantages for pharmaceutical manufacturing.
Patent CN110592035B reveals high-efficiency carbonyl reductase mutants for chiral alcohol production, offering significant supply chain and cost advantages.
Novel enzymatic synthesis for Telotristat ethyl intermediates ensures high purity and scalable supply chain solutions for global pharmaceutical manufacturers seeking cost efficiency.
Patent CN113174377B reveals a stable carbonyl reductase mutant for synthesizing (2R,3S)-MPGM with 100% theoretical yield, offering significant cost reduction in API manufacturing.
Patent CN112941043B details a carbonyl reductase mutant for synthesizing chiral intermediates. Offers high yield and scalability for carbapenem antibiotic production supply chains.
Patent CN107022587A details a novel enzymatic route for Ezetimibe intermediates using tubular reactors. Discover cost reduction in API manufacturing and high-purity supply solutions.
Patent CN112852768B reveals engineered carbonyl reductase mutants for high-purity chiral nitrile synthesis, offering significant cost reduction in API manufacturing and scalable green chemistry solutions.
Patent CN113816836A details enzymatic route for liver drug intermediate. High purity, scalable, cost-effective supply chain solution.
Patent CN119876067B reveals high-activity carbonyl reductase mutants for diltiazem intermediates, offering scalable biocatalytic solutions for pharmaceutical manufacturing.
Patent CN102618513B details a robust biocatalytic route for API intermediates, offering high ee values and scalability without expensive cofactors.
Patent CN121065123A reveals enhanced enzyme stability for chiral alcohol manufacturing cost reduction and supply reliability.
Novel carbonyl reductase mutants enhance thermal stability and yield for pharmaceutical intermediates like florfenicol and statins, offering cost-effective biocatalytic solutions.
Patent CN104630242B reveals novel biocatalytic routes for chiral intermediates. Enhances supply chain reliability and reduces heavy metal dependency in manufacturing.
Patent CN117089533A details novel carbonyl reductase mutants enabling cost reduction in chiral alcohol manufacturing with high stereoselectivity and supply reliability.
Patent CN113652407B reveals a novel carbonyl reductase mutant enabling strict S-selectivity and enhanced activity for cost-effective chiral diol manufacturing.